chevron_leftBack
As of 24 June 2026, Semnur Pharmaceuticals, Inc. has a market cap of $115.1M USD, ranking #24549 globally and #3834 in the United States.
It ranks #2190 in the Healthcare sector, and #794 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$115.1MUSD
Enterprise Value
$1.17BUSD
Net Income (TTM)
-$160.42MUSD
PB Ratio
-55.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Henry Ji
open_in_new
Employees
10
Founded
2013
Website
semnurpharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | -38% | -38% | -43% | -44% | -58% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SMNR
ISIN: US81686G1058
Shares Out.:
Shares Outstanding:
230.209M1
Shares Float:
29.154M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
5.00 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
662K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
475K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
313K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
238K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
130K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
102K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$316.71B
275K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$285.49B
248K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$270.54B
235K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$179.71B
156K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$108.83B
94K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$107.21B
93K%
80.96B GBP
|
14.6
|
chevron_leftBack